Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis

Immunosuppressive pathways active within the tumor microenvironment must be targeted in combination to sufficiently bolster antitumor immune defenses. Inhibition of A(2A) adenosine receptor signaling in combination with immune checkpoint blockade enhances CD8(+) T and NK cell anti-metastatic activity. This results in reduced metastatic burden and improved survival in pre-clinical models.